Novel imipridone combination therapies targeting oncohistone H3K27M mutant diffuse midline glioma (DMG)

被引：0
作者：
Borsuk, Robyn [1 ]
Zhou, Lanlan [2 ,3 ,4 ,5 ,6 ]
Lulla, Rishi [1 ]
El-Deiry, Wafik [2 ,3 ,4 ,5 ,6 ]
机构：
[1] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA
[2] Brown Univ, Joint Program Canc Biol, Providence, RI 02912 USA
[3] Lifespan Canc Inst, Providence, RI USA
[4] Brown Univ, Dept Pathol & Lab Med, Providence, RI 02912 USA
[5] Lifespan, Dept Med, Hematol Oncol Div, Providence, RI USA
[6] Brown Univ, Providence, RI 02912 USA
来源：
CANCER RESEARCH | 2020年 / 80卷 / 16期
关键词：
D O I：
10.1158/1538-7445.AM2020-5407
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5407
引用
收藏
页数：2
相关论文
共 50 条
  • [31] REVERTANCE OF THE H3K27M MUTATION RESCUES CHROMATIN MARKS NECESSARY FOR ONCOGENESIS IN DIFFUSE MIDLINE GLIOMA
    Nesvick, Cody
    Day, Charles
    Zhang, Liang
    Hinchcliffe, Edward
    Daniels, David
    NEURO-ONCOLOGY, 2020, 22 : 302 - 302
  • [32] Developing H3K27M mutant selective radiosensitization strategies in diffuse intrinsic pontine glioma
    Parsels, Leslie A.
    Wahl, Daniel
    Koschmann, Carl
    Morgan, Meredith A.
    Zhang, Qiang
    NEOPLASIA, 2023, 37
  • [33] AVAPRITINIB FOR TARGETING PDGFRA IN H3K27M-MUTATED DIFFUSE MIDLINE GLIOMA
    Mayr, Lisa
    Madlener, Sibylle
    Weiler-Wichtl, Liesa
    Rosenmayr, Verena
    Furtner-Srajer, Julia
    Guntner, Armin
    Stepien, Natalia
    Baumgartner, Alicia-Christina
    Dorfer, Christian
    Haberler, Christine
    Muellauer, Leonhard
    Palova, Hana
    Pokorna, Petra
    Sterba, Jaroslav
    Dieckmann, Karin
    Azizi, Amedeo
    Peyrl, Andreas
    Kim, Sean
    Hsieh, Antony
    Dimitrijevic, Sasa
    Gojo, Johannes
    NEURO-ONCOLOGY, 2022, 24 : 32 - 32
  • [34] ELONGIN B REGULATES H3K27M CHROMATIN INCORPORATION TO PROMOTE MALIGNANCY IN DIFFUSE MIDLINE GLIOMA
    Anastas, Jamie
    Kebede, Adam
    Jiao, Alan
    Mimoso, Claudia
    Murdaugh, Rebecca
    Zee, Barry
    Filbin, Mariella
    Adelman, Karen
    Shi, Yang
    NEURO-ONCOLOGY, 2023, 25
  • [35] Targeting H3K27 Mutant Diffuse Midline Glioma Via Glucosylceramide Synthase Inhibitors
    Paret, C.
    Sandhoff, R.
    ElMalki, K.
    Wingerter, A.
    Zahnreich, S.
    Frauenknecht, K.
    Lehmann, N.
    Alexandra, R.
    Moisch, M.
    Faber, J.
    PEDIATRIC BLOOD & CANCER, 2021, 68 : S115 - S115
  • [36] THE COMBINATION THERAPY OF PARP INHIBITOR AND TMZ IN DIFFUSE MIDLINE GLIOMA HARBORING H3 K27M-MUTANT
    Ohba, Shigeo
    Hashizume, Rintaro
    Hirose, Yuichi
    NEURO-ONCOLOGY, 2020, 22 : 64 - 64
  • [37] A first-in-human peptide vaccine targeting H3K27M; encouraging early findings in 8 adults with diffuse midline glioma
    Hotchkiss, Kelly M.
    Cho, Eugene J.
    Khasraw, Mustafa
    NEURO-ONCOLOGY, 2024, 26 (01) : 5 - 6
  • [38] LONGITUDINAL MONITORING OF PLASMA H3K27M IN DIFFUSE MIDLINE GLIOMA PATIENTS TREATED WITH ONC201
    Tarapore, Rohinton S.
    Field, Amanda
    Hill, D. Ashley
    Allen, Joshua
    NEURO-ONCOLOGY, 2020, 22 : 11 - 11
  • [39] H3K27M mutant glioma: Disease definition and biological underpinnings
    Saratsis, Amanda M.
    Knowles, Truman
    Petrovic, Antonela
    Nazarian, Javad
    NEURO-ONCOLOGY, 2024, 26 : S92 - S100
  • [40] Diffuse Midline Glioma H3 K27M-Mutant Manifested as Progressive Paraplegia
    Goldstein, Eric D.
    Kyper, Christopher M.
    Siegel, Jason L.
    NEUROHOSPITALIST, 2020, 10 (01) : 73 - 74
12345